After an inspection of Hospira’s medical device quality systems in Lake Forest, Ill., the FDA issued a list of 10 objectionable conditions in a Form 483. So far in 2013, the company has sent out 11 device notifications, including recalls and corrections.
Hospira’s Clayton, N.C., facility recently resumed producing propofol, and plans to re-launch the drug shortly.
More Articles on Anesthesia:
ASA Opposes Proposed Changes to Opioid Labels by FDA
Dr. Shawn Crook Joins Bothwell Regional Health Center
Hamilton Medical Anesthesia Ventilator Contains Software Problems
